Olivia and Tom Walton have committed an initial $100M to Healthy Moms, Healthy Babies America. The money is small next to the problem — which is exactly why it is structured as matching capital.
Semaglutide started at the mouse equivalent of late middle age added about 100 days of life and improved memory, muscle and blood sugar. The animals were neither obese nor diabetic — which is what makes the result interesting.
The phase 3 LONESTAR trial tested a widely assumed strategy — radiate or resect what remains after checkpoint blockade — and found no survival benefit, not even in the oligometastatic patients it was supposed to help most.
Adding a coronary calcium score to the AHA’s PREVENT calculator barely moved overall accuracy across 6,000 adults. But in the borderline-risk zone, a high score meant roughly seven times the event rate of a zero.
Scholar Rock’s Isembyld (apitegromab) attacks spinal muscular atrophy from a new direction — the muscle itself — and is designed to layer on top of the nerve-focused drugs that transformed the disease over the past decade.
Nutromics’ microneedle patch continuously measures the antibiotic vancomycin in the body — aiming to replace repeated blood draws and prevent the kidney damage that comes from getting the dose wrong.
NICE has declined to recommend Gilead’s lenacapavir for HIV prevention, calling it poor value for money — a decision HIV charities call a missed opportunity to end new infections.
A genomic study of long-lived bats found their secret may be an exceptionally vigilant immune system — and cells that would rather self-destruct than risk becoming cancerous. It is a fresh angle on one of biology’s enduring puzzles.
Camizestrant missed its main goal in the broad first-line SERENA-4 study, cooling expectations for a blockbuster hopeful even as the same drug had just earned an FDA approval in a narrower, biomarker-defined group.
New figures from the World Trade Center Health Program show a sharp jump in certified cancers — a sobering reminder that the health toll of that day is still unfolding, and that survivors, not just responders, are increasingly affected.
UCLA researchers grew trillions of tumor-hunting T cells from a few cord-blood stem cells — enough for thousands of doses — and, in mice, controlled cancer without the dangerous complication that has long plagued donor-cell therapies.
In a six-month trial, people with Type 1 diabetes and obesity who ate only between noon and 8 p.m. saw better glucose control than calorie-cutters — with no rise in the dangerous highs and lows that make fasting fraught in this group.